Monitor pipeline development timelines for QTORIN rapamycin and pitavastatin; assess future cash burn and potential for additional dilution. The capital raise extends runway but does not alter near-term clinical risk profile.
Price Chart
Executive Summary
Palvella Therapeutics completed an upsized public offering of 1,840,000 shares at $125.00 per share, generating $230 million in gross proceeds. The capital will fund development of its QTORIN pipeline, including rapamycin and pitavastatin programs, and support general corporate purposes.
Key Financial Metrics
Key Facts
- Palvella closed a public offering of 1,840,000 shares of common stock at $125.00 per share.
- The offering included full exercise of the underwriters' option to purchase 240,000 additional shares.
- Gross proceeds totaled $230 million before underwriting discounts and expenses.
- Proceeds will be used to advance QTORIN rapamycin and QTORIN pitavastatin programs, and for working capital and R&D.
- The offering was conducted under a shelf registration (Form S-3) declared effective January 29, 2026.
Financial Impact
$230 million in gross proceeds; dilution estimated at approximately 10-12% based on $1.6B market cap
Risk Factors
- Dilution to existing shareholders from issuance of new shares
- No assurance of clinical success for QTORIN pipeline candidates
- Forward-looking statements about use of proceeds subject to execution risk
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3247266 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 2, 2026 4w ago | 144 | $155.47 $132.47 | ▼ −14.79% | ▼ −13.61% | $132.47 (−14.79%) |
Aug 9, 2026 7w ago | Institutional Cluster | $152.22 $157.00 | ▲ +3.14% | ▲ +4.05% | $132.47 (−12.97%) |
Aug 4, 2026 8w ago | 8-K | $151.99 $150.55 | ▼ −0.95% | ▲ +0.29% | $132.47 (−12.84%) |
Jul 30, 2026 9w ago | Press Release | $150.19 $150.33 | ▲ +0.09% | ▼ −3.87% | $132.47 (−11.80%) |
Jul 28, 2026 9w ago | Press Release | $142.84 $148.24 | ▲ +3.78% | ▲ +0.40% | $132.47 (−7.26%) |
Jun 30, 2026 13w ago | 8-K | $152.82 $141.77 | ▼ −7.23% | ▼ −6.20% | $132.47 (−13.32%) |
Jun 22, 2026 14w ago | Press Release | $118.84 $157.24 | ▲ +32.31% | ▲ +32.46% | $132.47 (+11.47%) |
Jun 16, 2026 15w ago | 8-K | $110.12 $149.68 | ▲ +35.92% | ▲ +35.72% | $132.47 (+20.30%) |
Jun 11, 2026 16w ago | Institutional Cluster | $106.38 $151.04 | ▲ +41.98% | ▲ +40.09% | $132.47 (+24.53%) |
May 15, 2026 20w ago | 8-K | $114.24 $116.51 | ▲ +1.99% | ▼ −0.13% | $132.47 (+15.96%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access